目录号 | 产品详情 | 靶点 | |
---|---|---|---|
T10607 | Autophagy | ||
BRD5631 是一种自噬 (autophagy) 增强剂,通过与 mTOR 无关的通路来增强自噬。BRD5631 能够影响先前与自噬相关的几种细胞疾病表型,包括蛋白聚集、细胞存活、细菌复制和炎性因子的产生。BRD5631可以作为一种有价值的工具,用于研究自噬在细胞稳态和疾病中的作用。 | |||
T36308 | |||
PF-06843195 is a highly selective PI3Kα inhibitor with an IC50 of 18 nM in Rat1 fibroblasts. The Kis of PF-06843195 for PI3Kα and PI3Kδ in biochemical kinase assay are less than 0.018 nM and 0.28 nM, respectively. PF-06843195 has great suppression of the PI3K/mTOR signaling pathway and durable antitumor efficacy[1]. PF-06843195 inhibits the breast cancer cell lines MCF7 and T47D proliferation with IC50s of 62 nM and 32 nM, respectively[1].PF-06843195 inhibits pAKT (T308) in MCF7 and T47D cells with IC50s of 7.8 nM and 8.7 nM, respectively[1]. In rats, PF-06843195 can rapidly and quantitatively transform from PF-06862309[1].PF-06843195 exhibits oral bioavailability (rat 25 %) following oral administration (rat 10 mg/kg)[1].PF-06843195 exhibits a moderate half-life (rat 3.6 h) due to high plasma clearance (30 mL/min/kg) combined with large volumes of distribution (3.0 L/kg) following intravenous administration (rat 2 mg/kg)[1]. [1]. Hengmiao Cheng, et al. Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195). J Med Chem. 2021 Jan 14;64(1):644-661. | |||
T73301 | |||
ATR-IN-20是一种高效的ATR(ATM/ATR)抑制剂, IC50值仅为3 nM。该化合物还能抑制mTOR(IC50值为18 nM),并展示出对PI3Kα(100 nM)、ATM(100 nM)和DNA-PK(662 nM)的良好选择性。ATR-IN-20具备优秀的药代动力学属性(F=30%),同时显示了其抗癌潜力。 | |||
T38263 | |||
TBK1/IKKε-IN-4 is a 6-aminopyrazolopyrimidine derivative and a potent, selective TBK1 and IKKε inhibitor with IC50 values of 13 nM and 59 nM, respectively. TBK1/IKKε-IN-4 shows 100- to 1000-fold less activity against other protein kinases including PDK1, PI3K family members and mTOR[1]. TBK1/IKKε-IN-4 (Compound II; 96 hours; A549 andHCC44 cells) treatmentdisplays selective toxicity in TBK1-dependent cancer cell lines (IC50 of ~ 4.2 μM for H441 cells and IC50 of ~0.4 μM for A549 cells)[1].TBK1/IKKε-IN-4 (Compound II; 0-2 μM; 30 minutes; HCC44 cells) treatment inhibits the AKT activity[1].TBK1/IKKε-IN-4 (Compound II) inhibits LPS-induced expression of IFNβ (IC50 =62 nM), and the IFNβ target genes IP10 (IC50 =78 nM) and Mx1 (IC50=20 nM). TBK1/IKKε-IN-4 effectively blocksTLR3-dependent IRF3 nuclear translocation in cells with an IC50 under 100 nM, but does not impair TNFR1-dependent p65 NFκB nuclear translocation with doses as high as 20 μM[1]. [1]. Ou YH, et al. TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. Mol Cell. 2011 Feb 18;41(4):458-70. | |||
T35529 | Others | ||
hSMG-1 inhibitor 11e 是一种有效的选择性 hSMG-1 抑制剂 (IC50 <0.05 nM),可用于癌症治疗研究。 | |||
T82971 | |||
ARI-1是一种针对受体酪氨酸激酶样孤儿受体ROR1的抑制剂,对于ROR1异常表达所致的非小细胞肺癌(NSCLC)及EGFR-TKI诱导的耐药性治疗具有显著效果。该化合物能够特异性结合至ROR1的胞外卷曲结构域,并以ROR1依赖性方式抑制PI3K/AKT/mTOR信号通路,进而有效地阻断NSCLC细胞的增殖和迁移。此外,ARI-1还展现了显著的体内抗肿瘤活性。 | |||
T3705 | PI3K mTOR | ||
GDC0084 (RG7666) 是一种具有潜在抗肿瘤活性的 PI3K 抑制剂。 GDC0084 (RG7666) 特异性抑制 PI3K/AKT 激酶(或蛋白激酶 B)信号通路中的 PI3K,从而抑制 PI3K 信号通路的激活。这可能导致易感肿瘤细胞群中的细胞生长和存活受到抑制。 | |||
T127402 | |||
Coenzyme Q0 (CoQ0),一种从Antrodia cinnamomea提取的口服醌类化合物,具备促进细胞凋亡(apoptosis)与自噬(autophagy)的作用。该化合物通过抑制HER-2/AKT/mTOR信号通路,增强凋亡和自噬机制;同时,调控NFκB/AP-1活化,提升Nrf2稳定性,从而缓解炎症及氧化还原失衡。此外,Coenzyme Q0还表现出抗血管生成特性,通过下降MMP-9/NF-κB并提升HO-1信号路径发挥作用。 | |||
TN5050 | NADPH-oxidase VEGFR p38 MAPK ROS Akt PI3K mTOR p53 | ||
Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis, it can strongly suppress tumor angiogenesis in human umbilical vein endothelial cells, it blocks vascul | |||
T68485 | |||
Apilimod dimesylate is a potent and selective PIKfyve inhibitor. It exhibits no significant activity at other lipid kinases and protein kinases, including PIP4K, PIP5K, mTOR, PI3K and PI4K. Apilimod dimesylate inhibits cellular entry by SARS-CoV-2, MERS-CoV and MHV S pseudovirions. It reduces the number of SARS-CoV-2-infected hiPSC-derived pneumocyte-like cells by 85% and inhibits SARS-CoV-2 replication in donor lung tissue. It also exhibits selective cytotoxicity in B-cell non-Hodgkin lymphoma compared with normal cells and inhibits production of IL-12 and IL-23. Apilimod dimesylate is also anti-inflammatory and water-soluble. |
目录号 | 产品名/同用名 | 种属 | 表达系统 | ||
---|---|---|---|---|---|
TMPH-02089 | mTOR Protein, Human, Recombinant (His & Myc) | Human | E. coli | ||
mTOR Protein, Human, Recombinant (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted molecular weight is 23.2 kDa and the accession number is P42345.
|
|||||
TMPY-02252 | LAMTOR2 Protein, Human, Recombinant (His) | Human | E. coli | ||
Ragulator complex protein LAMTOR2, also known as Endosomal adaptor protein p14, Late endosomal/lysosomal Mp1-interacting protein, Late endosomal/lysosomal adaptor and MAPK and MTOR activator 2, Mitogen-activated protein-binding protein-interacting protein, Roadblock domain-containing protein 3, LAMTOR2, MAPBPIP, and ROBLD3, is a protein which belongs to the GAMAD family. LAMTOR2 / ROBLD3 is a regulator of the TOR pathway, a signaling cascade that promotes cell growth in response to growth factors, energy levels, and amino acids. As part of the Ragulator complex, LAMTOR2 / ROBLD3 recruits the Rag GTPases and the mTORC1 complex to lysosomes, a key step in the activation of the TOR signaling cascade by amino acids. LAMTOR2 / ROBLD3 is an adapter protein that enhances the efficiency of the MAP kinase cascade facilitating the activation of MAPK2. Defects in LAMTOR2 are the cause of immunodeficiency due to defects in MAPBP-interacting protein (ID-MAPBPIP). This form of primary immunodeficiency syndrome includes congenital neutropenia, partial albinism, short stature, and B-cell and cytotoxic T-cell deficiency.
|
|||||
TMPJ-01378 | Mp1 Protein, Human, Recombinant (His) | Human | E. coli | ||
Mitogen-Activated Protein Kinase Scaffold Protein 1 (MAPKSP1) was identified as an interacting protein that belongs to the LAMTOR3 family. MAPKSP1 restricted to late endosomes by the mitogen-activated protein-binding protein-interacting protein, and binds specifically to MAP kinase kinase MAP2K1/MEK1, MAP kinase MAPK3/ERK1, and MAP kinase MAPK1/ERK2. MAPKSP1 interacts with MAP2K1/MEK1 and MAPK2 and enhances the activation of MAPK2, and thus is thought to function as an adaptor to enhance the efficiency of the MAP kinase cascade.
|
|||||
TMPY-04540 | S6K1/RPS6KB1 Protein, Human, Recombinant (GST) | Human | Baculovirus Insect Cells | ||
PS6K, also known as RPS6KB1, is a serine/threonine-protein kinase. It belongs to the RSK (ribosomal s6 kinase) family. Members of this family function in signal transduction. PS6K is an isoform of p70 ribosomal S6 kinase (S6K). S6K can be activated by mitogenic stimuli such as growth factors, insulin and cytokines. It phosphorylates the ribosomal protein S6. PS6K also phosphorylates other proteins such as elF4B, eEF2K and SKAR. It is a crucial effector of mTOR(rapamycin) signaling. PS6K is dissociated from the EIF3 complex and activated upon mitogenic stimulation, phosphorylation by the mammalian target of mTOR complex 1 (mTORC1). Its active form then phosphorylates and activates several substrates in the preinitiation complex, including the EIF2B complex and the cap-binding complex component EIF4B. PS6K also functions in cell proliferation, cell growth and cell cycle progression.
|
|||||
TMPK-00524 | CA9/Carbonic Anhydrase IX Protein, Cynomolgus, Recombinant (His) | Cynomolgus | HEK293 Cells | ||
CA9 is a member of the carbonic anhydrases' family, that is often expressed in cancer cells under hypoxic condition. CA9 expression potentially contributes to the regulation of cancer cell differentiation and mediates tumour-associated genes and signalling pathways, including apoptosis, hypoxia, G2M checkpoint, PI3K/AKR/mTOR signalling and TGF-beta signalling pathways. CA9/Carbonic Anhydrase IX Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 41.03 kDa and the accession number is A0A2K5VQG9.
|
|||||
TMPK-00283 | CA9/Carbonic Anhydrase IX Protein, Human, Recombinant (His & Avi) | Human | HEK293 Cells | ||
CA9 is a member of the carbonic anhydrases' family, that is often expressed in cancer cells under hypoxic condition. CA9 expression potentially contributes to the regulation of cancer cell differentiation and mediates tumour-associated genes and signalling pathways, including apoptosis, hypoxia, G2M checkpoint, PI3K/AKR/mTOR signalling and TGF-beta signalling pathways. CA9/Carbonic Anhydrase IX Protein, Human, Recombinant (His & Avi) is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 43.7 kDa and the accession number is Q16790.
|
|||||
TMPY-06821 | THRB Protein, Human, Recombinant (His) | Human | E. coli | ||
Thyroid hormone receptor beta (THRB), also known as TRbeta and NR1A2, belongs to the nuclear hormone receptor family. Featuring an N-terminal transactivation domain, a central DNA-binding domain, and a hormone/ligand-binding domain, THRB isoform 1/2 expression localizes predominately to the liver and pituitary, respectively. THRB regulates the feedback of T3-dependent thyrotropin-stimulating hormone (TSH) transcription in the pituitary by binding to thyroid hormone (TH) response elements present on promoters of TH-responsive genes. Located on chromosome 3p24, THRB gene mutation has been linked to autosomal dominant resistance to TH (RTH), which is characterized by goiter and elevated levels of T3, T4, and TSH. THRB is a known pharmacological target for the treatment of non-alcoholic steatohepatitis (NASH). THRB may be a target for future cancer therapies since its knockdown enhanced the viability of endometrial cancer cells and activated the mTOR-4EBP1/eIF4G pathway.
|
|||||
TMPH-02855 | PML Protein, Mouse, Recombinant (His & Myc) | Mouse | E. coli | ||
Functions via its association with PML-nuclear bodies (PML-NBs) in a wide range of important cellular processes, including tumor suppression, transcriptional regulation, apoptosis, senescence, DNA damage response, and viral defense mechanisms. Acts as the scaffold of PML-NBs allowing other proteins to shuttle in and out, a process which is regulated by SUMO-mediated modifications and interactions. Positively regulates p53/TP53 by acting at different levels (by promoting its acetylation and phosphorylation and by inhibiting its MDM2-dependent degradation). Regulates phosphorylation of ITPR3 and plays a role in the regulation of calcium homeostasis at the endoplasmic reticulum. Regulates RB1 phosphorylation and activity. Acts as both a negative regulator of PPARGC1A acetylation and a potent activator of PPAR signaling and fatty acid oxidation. Regulates translation of HIF1A by sequestering MTOR, and thereby plays a role in neoangiogenesis and tumor vascularization. Regulates PER2 nuclear localization and circadian function. Cytoplasmic PML is involved in the regulation of the TGF-beta signaling pathway. Required for normal development of the brain cortex during embryogenesis. Plays a role in granulopoiesis or monopoiesis of myeloid progenitor cells. May play a role regulating stem and progenitor cell fate in tissues as diverse as blood, brain and breast. Shows antiviral activity towards lymphocytic choriomeningitis virus (LCMV) and the vesicular stomatitis virus (VSV).
|